BRAIN Biotech AG | Deep Dive: CRISPR Cas9 | Michael Schneiders, Investor Relations
seat11a - Gateway to In-Depth Financial Insights
0:00 / 0:00
BRAIN Biotech AG | Deep Dive: CRISPR Cas9 | Michael Schneiders, Investor Relations
1 831 просмотр · 5 л. назад
seat11a - Gateway to In-Depth Financial Insights
2,56 тыс. подписчиков
1 831 просмотр · 5 л. назад
Welcome to seat11a, in today’s video we are presenting Michael Schneiders, Head of IR of BRAIN AG
Michael will present the latest Product Highlights of BRAIN
▶️ Visit us: https://seat11a.com/
▶️ In this video Richard explains:
00:00 Brain
00:14 Intro
00:34 Mega-Trends for Brain
03:19 What´s new at Brain
03:48 Pha 121 / Pharvaris
06:28 CRISPR-Cas Genome Editing Tool
10:28 Incubator: Future Business
11:07 Biotalatysts Ltd.
12:13 Contact
Company Profile
BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy.
BRAIN is the parent company of the BRAIN Group.
Two pillars form BRAIN Group’s business:
The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company’s own highly innovative products.
In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances.
Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry.
The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.
Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
----------------------------
▶️ Visit us: https://seat11a.com/
----------------------------
▶️ Other videos:
Elevator Pitch: https://seat11a.com/investor-relation...
Company Presentation: https://seat11a.com/investor-relation...
Deep Dive Presentation: https://seat11a.com/investor-relation...
Financial Results Presentation: https://seat11a.com/investor-relation...
ESG Presentation: https://seat11a.com/investor-relation...
-----------------------------
▶️ About seat11a:
Seat11a is the next-generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime.
-----------------------------
✅ Disclaimer:
this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/